Safety of unoprostone isopropyl 0.15% ophthalmic solution in patients with mild to moderate asthma

Ophthalmologica

Volumn 217, Issue 2, 2003, Pages 129-136

  Gunawardena, Kulasiri A ^a   Crame, Nathan ^a   Mertz, Beat ^b   Shams, Naveed ^c,d  

^a Chiltern International   (United Kingdom)

^b Novartis Ophthalmics AG   (Switzerland)

^c Novartis Ophthalmics Inc   (United States)

^d Clin R D Americas Novartis O   (United States)

Author keywords

Asthma; Bronchodilator; Docosanoid; Glaucoma; Unoprostone

Indexed keywords

EYE DROPS; SALBUTAMOL; UNOPROSTONE ISOPROPYL ESTER;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EYE BURNING; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LACRIMATION; LUNG FUNCTION TEST; MALE; MEDICAL ASSESSMENT; OCULAR PRURITUS; PEAK EXPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DINOPROST; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; RESPIRATORY FUNCTION TESTS; SAFETY; SPIROMETRY; TREATMENT OUTCOME;

EID: 0037286617     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068558     Document Type: Article

References (32)

1. Gupta N, Weinreb RN: New definitions of glaucoma. Curr Opinion Ophthalmol 1997;8:38-41.
2. European Glaucoma Society: Terminology and Guidelines for Glaucoma. Savona, Dogma, 1998.
3. Armaly MF, Krueger DE, Mauder L, Becher B, Hetherington J Jr, Kokker AE, Levene RZ, Maumenee AE, Pollack IP, Shaffer RN: Biostatistical analysis of the glaucoma study I. Summary report of risk factors for glaucomatous visual field defect. Arch Ophthalmol 1980;98:2163-2171.
4. Kitazawa Y, Horie T, Aoki S, Suzuki M, Nishioka K: Untreated ocular hypertension. A long-term prospective study. Arch Ophthalmol 1977;95:1180-1184.
5. Robin A: Glaucoma management: Beyond intraocular pressure (1997). Ophthalmol Times 1998(suppl 2);S2-S8.
6. Lesar TS: Glaucoma; in DiPiro JT, Talbert RL, Hayes PE, Matzke GT, Posey LM (eds): Pharmacotherapy: A pathophysiologic approach, ed 2. Norwalk, Appleton & Lange, 1993, pp 1363-1367.
7. Passo MS, Palmer EA, Van Buskirk EM: Plasma timolol in glaucoma patients. Ophthalmology 1984;91:1361-1363.
8. Alvan G, Caissendorff B, Seideman P, Widmark K, Widmark G: Absorption of ocular timolol. Clin Pharmacokinet 1980;5:95-100.
9. Vonwill A, Landold M, Flammer J, Bachofen H: Bronchostriction side effects of timolol eye drops in patients with obstructive lung disease. Schweiz Med Wochenschr 1981;111:655-659.
10. Sakurai M, Araie M, Oshika T, Mori M, Shoji N, Masuda K: Effects of topical application of UF-021, a novel prostaglandin-related compound, on aqueous humor dynamics in rabbit. Jpn J Ophthalmol 1993;37:252-258.
11. Yamamoto T, Chi Q, Kitazawa Y: Interaction between a prostaglandin F2 alpha derivative, UF-021, and pilocarpine in ocular hypotensive therapy. Nippon Ganka Gakkai Zasshi 1994; 98:2020-2205.
12. Yoshida S, Deguchi T, Osama H, Ueno R: The Mechanism of IOP-lowering action of Rescula®, a new therapeutic agent for glaucoma and ocular hypertension in various animals-comparison with prostaglandin F2α. Clin Rep 1994;28:3827-3838.
13. Taniguchi T, Haque MSR, Sugiyama K, Hori N, Kitazawa Y: Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits. J Ocul Pharmacol Ther 1996;12:96-103.
14. Taniguchi T, Sawada A, Sugiyama K, Kawakami H, Tsuji A, Kitazawa Y: Ocular hypotensive effects and mechanisms of prostglandin-related drugs (abstract). Invest Ophthalmol Vis Sci 1997;38:3794-B395.
15. Yuguchi M: Ocular hypotensive action of isopropyl unoprostone. J Eye (Atarashii Ganka) 1998;15:987-990.
16. Thieme H, Stumpff F, Ottlecz A, Percicot CL, Lambrou GN, Wiederholt M: Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 2001; 42:3193-3201.
17. Sharpe ED, Kapik B, Reaves A, Haque R, Shams N: Comparison of the effect of different concentrations of the docosanoid unoprostone isopropyl on intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension (abstract). Invest Ophthalmol Vis Sci 2001;42(suppl):S822.
18. Mundorf TK, Kapik B, Reaves A, Haque R, Shams NBK: Comparison of the effects of dosing regimen of the docosanoid unoprostone isopropyl 0.12% on intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension (abstract). Invest Ophthalmol Vis Sci 2001;42(suppl):S820.
19. Nordmann, J-P, Mertz B, Yannoulis NC, Schwenninger C, Kapik B, Shams N, and the Unoprostone Monotherapy Study Group: A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma (including pseudoexfoliation glaucoma), or ocular hypertension. 6-Month data. Am J Ophthalmol 2002;133:1-10.
20. Hommer AB, for The Unoprostone Study Group, Kapik B, and Shams N: Unoprostone as adjunctive therapy to timolol: A double-masked randomized study versus brimonidine and dorzolamide. Br J Ophthalmol, in press.
21. National Institutes of Health: National Heart, Lung and Blood Institute Guidelines for the diagnosis and management of asthma. Expert Panel Report 2 NIH July 1997 Publ No 97-4051.
22. American Thoracic Society: Standardization of Spirometry 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136.
23. Quanjer PH: Standardization of lung function testing. Bull Eur Physiopathol Respir 1983; 19(suppl 5):1-95.
24. Schoene RB, Martin TR, Charan MB, French CL: Timolol-induced bronchospasm in asthmatic bronchitis. JAMA 1981;1245:1460.
25. Botet C, Grau J, Benito P, Coll J, Vivancos J: Timolol ophthalmic solution and respiratory arrest. Ann Intern Med 1986;105:306-307.
26. Quigley HA: Open-angle glaucoma. N Engl J Med 1993;328:1097-1106.
27. Taniguchi T, Kitazawa Y: A risk-benefit assessment of drugs used in the management of glaucoma. Drug Safety 1994;11:68-74.
28. Diggory P, Franks W: Medical treatment of glaucoma - A reappraisal of the risks. Br J Ophthalmol 1996;80:85-89.
29. Liesegang TJ: Glaucoma: Changing concepts and future directions. Mayo Clin Proc 1996;7:689-694.
30. Stewart WC, Stewart JA, Crockett S, Kubilus C, Brown A, Shams N: Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5%, and placebo in healthy adults during exercise using a treadmill test. Acta Ophthalmol Scand, in press.
31. Stewart WC, Mundorf T, Haque R, Brown A, Kapik B, Shams N, and the Unoprostone Study Group: Comparison of the IOP-lowering efficacy and safety of the docosanoid unoprostone isopropyl 0.15% versus timolol maleate 0.5% dosed twice daily for 6 months in patients with primary open-angle glaucoma or ocular hypertension (abstract). Invest Ophthalmol Vis Sci 2001;42(suppl):S557.
32. Azuma I, Masuda K, Kitazawa Y, Takase M, Yamamura H: Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993;37:514-525.